Study aim: Investigating the effect of nanocurcumin on brain volumetery and cognitive function in patients with Alzheimer’s disease Design: A randomized, double blinded ,and controlled clinical trial with 30 patients with Alzheimer’s disease who will be classified in a group receiving nanocurcumin and a group receiving placebo and followed for 6 months during 2026. Settings and conduct: Patients with Alzheimer’s disease who diagnosed by a neurologist in Shiraz Emam Reza center or office enrolled based on inclusion criteria by a team member; then they receive nanocurcumin or placebo with double blind approach (patients and researchers) and will undergo brain MRI in Namazi hospital and perform cognitive test(MOCA) at the beginning of study and after 6 months. Participants/Inclusion and exclusion criteria: Inclusion criteria: Patients who diagnosed as mild or moderate Alzheimer’s disease based on DSM-5 and NIA-AA. 50-85 years old patients. Ability to do cognitive tests and MRI. Exclusion criteria: Patients with other neurological conditions like Parkinson’s disease and stroke. Use of anti inflammatory and antioxidants medications during study. Any contraindications for MRI Intervention groups: Some patients will take nanocurcumin and other patients will receive placebo Main outcome variables: Brain volume alterations(volumetery based on MRI)cognitive function alterations(MoCA test)